Exact Mass: 393.2726384

Exact Mass Matches: 393.2726384

Found 215 metabolites which its exact mass value is equals to given mass value 393.2726384, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Oxidized Cypridina luciferin

1-(3-{6-(1H-indol-3-yl)-3-[(2S)-2-methylbutanamido]pyrazin-2-yl}propyl)guanidine

C21H27N7O (393.2276972)


   

undecylprodigiosin

(2Z,5Z)-3-methoxy-5-pyrrol-2-ylidene-2-[(5-undecyl-1H-pyrrol-2-yl)methylidene]pyrrole

C25H35N3O (393.277998)


A member of the class of tripyrroles that is 1H-pyrrole substituted by (4-methoxy-1H,5H-[2,2-bipyrrol]-5-ylidene)methyl and undecyl groups at positions 2 and 5, respectively. It is a pigment produced by Stveptomyces coelicolor. D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents

   

2,2-Dimethyl-3-(4-methoxyphenyl)-4-ethyl-6-(1-pyrrolidinylmethyl)-2H-1-benzopyran-7-ol

2,2-Dimethyl-3-(4-methoxyphenyl)-4-ethyl-6-(1-pyrrolidinylmethyl)-2H-1-benzopyran-7-ol

C25H31NO3 (393.2303816)


   

2,2-Dimethyl-3-(4-methoxyphenyl)-4-ethyl-8-(1-pyrrolidinylmethyl)-2H-1-benzopyran-7-ol

2,2-Dimethyl-3-(4-methoxyphenyl)-4-ethyl-8-(1-pyrrolidinylmethyl)-2H-1-benzopyran-7-ol

C25H31NO3 (393.2303816)


   

Cyenopyrafen

(1E)-2-CYANO-2-[4-(1,1-DIMETHYLETHYL)PHENYL]-1-(1,3,4-TRIMETHYL-1H-PYRAZOL-5-YL)ETHENYL 2,2-DIMETHYLPROPANOATE

C24H31N3O2 (393.2416146)


   

Acidissiminol

N-[2-(4-{[(2E)-4-hydroxy-3,7-dimethylocta-2,6-dien-1-yl]oxy}phenyl)ethyl]benzenecarboximidate

C25H31NO3 (393.2303816)


Acidissiminol is found in beverages. Acidissiminol is an alkaloid from the fruit of Limonia acidissima (wood apple). Alkaloid from the fruit of Limonia acidissima (wood apple). Acidissiminol is found in beverages and fruits.

   

(5E,8E,11E)-Hexadeca-5,8,11-trienoylcarnitine

3-(hexadeca-5,8,11-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C23H39NO4 (393.28789340000003)


(5E,8E,11E)-Hexadeca-5,8,11-trienoylcarnitine is an acylcarnitine. More specifically, it is an (5E,8E,11E)-hexadeca-5,8,11-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5E,8E,11E)-Hexadeca-5,8,11-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5E,8E,11E)-Hexadeca-5,8,11-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Hexadeca-7,10,13-trienoylcarnitine

3-(hexadeca-7,10,13-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C23H39NO4 (393.28789340000003)


Hexadeca-7,10,13-trienoylcarnitine is an acylcarnitine. More specifically, it is an hexadeca-7,10,13-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Hexadeca-7,10,13-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Hexadeca-7,10,13-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(6E,9E,12E)-Hexadeca-6,9,12-trienoylcarnitine

3-(hexadeca-6,9,12-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C23H39NO4 (393.28789340000003)


(6E,9E,12E)-Hexadeca-6,9,12-trienoylcarnitine is an acylcarnitine. More specifically, it is an (6E,9E,12E)-hexadeca-6,9,12-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6E,9E,12E)-Hexadeca-6,9,12-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6E,9E,12E)-Hexadeca-6,9,12-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4E,7E,10E)-Hexadeca-4,7,10-trienoylcarnitine

3-(hexadeca-4,7,10-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C23H39NO4 (393.28789340000003)


(4E,7E,10E)-Hexadeca-4,7,10-trienoylcarnitine is an acylcarnitine. More specifically, it is an (4E,7E,10E)-hexadeca-4,7,10-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,7E,10E)-Hexadeca-4,7,10-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (4E,7E,10E)-Hexadeca-4,7,10-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(7Z,11Z,14Z)-Hexadeca-7,11,14-trienoylcarnitine

3-(hexadeca-7,11,14-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C23H39NO4 (393.28789340000003)


(7Z,11Z,14Z)-Hexadeca-7,11,14-trienoylcarnitine is an acylcarnitine. More specifically, it is an (7Z,11Z,14Z)-hexadeca-7,11,14-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7Z,11Z,14Z)-Hexadeca-7,11,14-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (7Z,11Z,14Z)-Hexadeca-7,11,14-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4E,7E,13E)-Hexadeca-4,7,13-trienoylcarnitine

3-(hexadeca-4,7,13-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C23H39NO4 (393.28789340000003)


(4E,7E,13E)-hexadeca-4,7,13-trienoylcarnitine is an acylcarnitine. More specifically, it is an (4E,7E,13E)-hexadeca-4,7,13-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,7E,13E)-hexadeca-4,7,13-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (4E,7E,13E)-hexadeca-4,7,13-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(6Z,10Z,14Z)-Hexadeca-6,10,14-trienoylcarnitine

3-(hexadeca-6,10,14-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C23H39NO4 (393.28789340000003)


(6Z,10Z,14Z)-Hexadeca-6,10,14-trienoylcarnitine is an acylcarnitine. More specifically, it is an (6Z,10Z,14Z)-hexadeca-6,10,14-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z,10Z,14Z)-Hexadeca-6,10,14-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6Z,10Z,14Z)-Hexadeca-6,10,14-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Palmitoyl Histidine

2-[(1-Hydroxyhexadecylidene)amino]-3-(1H-imidazol-5-yl)propanoate

C22H39N3O3 (393.2991264)


N-palmitoyl histidine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Palmitic acid amide of Histidine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Palmitoyl Histidine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Palmitoyl Histidine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

2,2-Dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide

2,2-Dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide

C23H39NO4 (393.28789340000003)


D004791 - Enzyme Inhibitors PD 128042 (CI 976) is a potent, orally active, and selective inhibitor of ACAT (acyl coenzyme A:cholesterol acyltransferase) with an IC50s of 73 nM. PD 128042 is also a potent LPAT (lysophospholipid acyltransferase) inhibitor. PD 128042 inhibits Golgi-associated LPAT activity (IC50=15 μM). PD 128042 inhibits multiple membrane trafficking steps, including ones found in the endocytic and secretory pathway[1][2][3].

   

undecylprodigiosin

3-methoxy-5-(1H-pyrrol-2-yl)-2-[(5-undecyl-1H-pyrrol-2-yl)methylidene]-2H-pyrrole

C25H35N3O (393.277998)


   

Estradiol 17-dihydrotrigonelline

5-hydroxy-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-trien-14-yl 1-methyl-1,4-dihydropyridine-3-carboxylate

C25H31NO3 (393.2303816)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

CCCCCCCC1=C(C)NC(C=C2C(=CC(=N2)C=2NC=CC=2)OC)=C1CCC

CCCCCCCC1=C(C)NC(C=C2C(=CC(=N2)C=2NC=CC=2)OC)=C1CCC

C25H35N3O (393.277998)


   

1-Piperazineacetamide, 4-((3,5-dimethoxy-4-hydroxy)dihydrocinnamoyl)-N-isopropyl-

1-Piperazineacetamide, 4-((3,5-dimethoxy-4-hydroxy)dihydrocinnamoyl)-N-isopropyl-

C20H31N3O5 (393.2263596)


   
   
   
   
   
   
   
   
   

Retreversine

N2-cyclohexyl-N6-[4-(4-morpholinyl)phenyl]-1H-purine-2,6-diamine

C21H27N7O (393.2276972)


   
   
   
   
   
   

MLS001077289-01!2-(2,2-DICYCLOHEXYLETHYL)PIPERIDINE 2-BUTENEDIOATE

"MLS001077289-01!2-(2,2-DICYCLOHEXYLETHYL)PIPERIDINE 2-BUTENEDIOATE"

C23H39NO4 (393.28789340000003)


   

MLS000028601-01!2-[2,2-DICYCLOHEXYLETHYL]PIPERIDINE MALEATE SALT

"MLS000028601-01!2-[2,2-DICYCLOHEXYLETHYL]PIPERIDINE MALEATE SALT"

C23H39NO4 (393.28789340000003)


   

Cypridinid oxyluciferin

Cypridinid oxyluciferin

C21H27N7O (393.2276972)


   
   
   
   
   
   
   
   
   
   

Reversine

N6-cyclohexyl-N2-[4-(4-morpholinyl)phenyl]-1H-purine-2,6-diamine

C21H27N7O (393.2276972)


   

PGH2-EA

N-(9S,11R-epidioxy-15S-hydroxy-5Z,13E-prostadienoyl)-ethanolamine

C23H39NO4 (393.28789340000003)


   

N-palmitoyl histidine

N-hexadecanoyl-histidine

C22H39N3O3 (393.2991264)


   

Acidissiminol

N-[2-(4-{[(2E)-4-hydroxy-3,7-dimethylocta-2,6-dien-1-yl]oxy}phenyl)ethyl]benzamide

C25H31NO3 (393.2303816)


   

CAR 16:3

3-[(4Z,7Z,10Z)-hexadecatrienoyloxy]-4-(trimethylazaniumyl)butanoate

C23H39NO4 (393.28789340000003)


   

C19 Sphingosine-1-phosphate

Nonadecaphing-4-enine-1-phosphate

C19H40NO5P (393.264396)


   

2-(2H-Benzotriazol-2-yl)-6-dodecyl-4-methylphenol

2-(2H-Benzotriazol-2-yl)-6-dodecyl-4-methylphenol

C25H35N3O (393.277998)


   

N,N,N,N,N-PENTAKIS(2-HYDROXYPROPYL)DIETHYLENETRIAMINE

N,N,N,N,N-PENTAKIS(2-HYDROXYPROPYL)DIETHYLENETRIAMINE

C19H43N3O5 (393.32025480000004)


   

2-Dicyclohexylphosphino-2-(N,N-dimethylamino)biphenyl

2-Dicyclohexylphosphino-2-(N,N-dimethylamino)biphenyl

C26H36NP (393.25852260000005)


   

2-(1-methyl-2,3,3a,4,5,6,7,7a-octahydroindol-3-yl)ethyl 2-hydroxy-2,2-diphenylacetate

2-(1-methyl-2,3,3a,4,5,6,7,7a-octahydroindol-3-yl)ethyl 2-hydroxy-2,2-diphenylacetate

C25H31NO3 (393.2303816)


   

Perhexiline maleate

Perhexiline maleate

C23H39NO4 (393.28789340000003)


C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker C93038 - Cation Channel Blocker Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina[1][2][5].

   

p-hexyloxybenzylidene p-octylaniline

p-hexyloxybenzylidene p-octylaniline

C27H39NO (393.3031484)


   

p-decyloxybenzylidene-p-butylaniline

p-decyloxybenzylidene-p-butylaniline

C27H39NO (393.3031484)


   
   
   
   
   

2-(Dicyclohexylphosphino)-N,N-dimethyl[1,1-biphenyl]-4-amine

2-(Dicyclohexylphosphino)-N,N-dimethyl[1,1-biphenyl]-4-amine

C26H36NP (393.25852260000005)


   
   

8-[1,1,2,2,3,3,4,4-octadeuterio-4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione,hydrochloride

8-[1,1,2,2,3,3,4,4-octadeuterio-4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione,hydrochloride

C21H23D8N5O2 (393.29798002399997)


   

(3S,5S)-5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-3-(3-methylbenzyl)piperidin-2-one

(3S,5S)-5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-3-(3-methylbenzyl)piperidin-2-one

C25H31NO3 (393.2303816)


   

s-Geranylgeranyl-l-cysteine

s-Geranylgeranyl-l-cysteine

C23H39NO2S (393.2701354)


An S-polyprenyl-L-cysteine where the polyprenyl moiety is specified as geranylgeranyl.

   

(3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl) 1-methyl-4H-pyridine-3-carboxylate

(3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl) 1-methyl-4H-pyridine-3-carboxylate

C25H31NO3 (393.2303816)


   

(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid

(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid

C20H31N3O5 (393.2263596)


   

L-Tyrosine, L-valyl-L-isoleucyl-

L-Tyrosine, L-valyl-L-isoleucyl-

C20H31N3O5 (393.2263596)


   
   

Methyl N-[(2S,3R)-3-amino-2-hydroxy-3-(4-methylphenyl)propanoyl]-D-alanyl-D-leucinate

Methyl N-[(2S,3R)-3-amino-2-hydroxy-3-(4-methylphenyl)propanoyl]-D-alanyl-D-leucinate

C20H31N3O5 (393.2263596)


   

N-Palmitoyl Histidine

2-[(1-Hydroxyhexadecylidene)amino]-3-(1H-imidazol-5-yl)propanoate

C22H39N3O3 (393.2991264)


N-palmitoyl histidine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Palmitic acid amide of Histidine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Palmitoyl Histidine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Palmitoyl Histidine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

(E,E,E)-geranylgeranylcysteine

(E,E,E)-geranylgeranylcysteine

C23H39NO2S (393.2701354)


   

3-[(3R,7R,10S,12S,13R,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]butanoate

3-[(3R,7R,10S,12S,13R,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]butanoate

C23H37O5- (393.2640852)


D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids

   

Hexadeca-7,10,13-trienoylcarnitine

Hexadeca-7,10,13-trienoylcarnitine

C23H39NO4 (393.28789340000003)


   

(5E,8E,11E)-Hexadeca-5,8,11-trienoylcarnitine

(5E,8E,11E)-Hexadeca-5,8,11-trienoylcarnitine

C23H39NO4 (393.28789340000003)


   

(6E,9E,12E)-Hexadeca-6,9,12-trienoylcarnitine

(6E,9E,12E)-Hexadeca-6,9,12-trienoylcarnitine

C23H39NO4 (393.28789340000003)


   

(4E,7E,10E)-Hexadeca-4,7,10-trienoylcarnitine

(4E,7E,10E)-Hexadeca-4,7,10-trienoylcarnitine

C23H39NO4 (393.28789340000003)


   

(4E,7E,13E)-Hexadeca-4,7,13-trienoylcarnitine

(4E,7E,13E)-Hexadeca-4,7,13-trienoylcarnitine

C23H39NO4 (393.28789340000003)


   

(7Z,11Z,14Z)-Hexadeca-7,11,14-trienoylcarnitine

(7Z,11Z,14Z)-Hexadeca-7,11,14-trienoylcarnitine

C23H39NO4 (393.28789340000003)


   

(6Z,10Z,14Z)-Hexadeca-6,10,14-trienoylcarnitine

(6Z,10Z,14Z)-Hexadeca-6,10,14-trienoylcarnitine

C23H39NO4 (393.28789340000003)


   
   
   

4-[4-[(1-Tert-butyl-5-tetrazolyl)-pyridin-4-ylmethyl]-1-piperazinyl]phenol

4-[4-[(1-Tert-butyl-5-tetrazolyl)-pyridin-4-ylmethyl]-1-piperazinyl]phenol

C21H27N7O (393.2276972)


   

(8S,9S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

(8S,9S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

C20H35N5O3 (393.27397600000006)


   

(4Z,7Z,11Z,13Z,15E,17S)-10,17-bis(hydroperoxy)docosa-4,7,11,13,15-pentaenoate

(4Z,7Z,11Z,13Z,15E,17S)-10,17-bis(hydroperoxy)docosa-4,7,11,13,15-pentaenoate

C22H33O6- (393.22770180000003)


   

(7Z,11Z,13Z,15E,19Z)-10,17-bis(hydroperoxy)docosa-7,11,13,15,19-pentaenoate

(7Z,11Z,13Z,15E,19Z)-10,17-bis(hydroperoxy)docosa-7,11,13,15,19-pentaenoate

C22H33O6- (393.22770180000003)


   
   
   

4-Hydroxy-6-(pyridin-3-yl)-3-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-2H-pyran-2-one

4-Hydroxy-6-(pyridin-3-yl)-3-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-2H-pyran-2-one

C25H31NO3 (393.2303816)


   

N-[[(2R,3S,4R)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-N-(2-methylpropyl)pyridine-2-carboxamide

N-[[(2R,3S,4R)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-N-(2-methylpropyl)pyridine-2-carboxamide

C24H31N3O2 (393.2416146)


   

N-[[(2R,3R,4R)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-N-(2-methylpropyl)pyridine-2-carboxamide

N-[[(2R,3R,4R)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-N-(2-methylpropyl)pyridine-2-carboxamide

C24H31N3O2 (393.2416146)


   

2-methoxy-N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

2-methoxy-N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

C20H31N3O5 (393.2263596)


   

2-methoxy-N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

2-methoxy-N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

C20H31N3O5 (393.2263596)


   

2-methoxy-N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

2-methoxy-N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

C20H31N3O5 (393.2263596)


   

2-methoxy-N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

2-methoxy-N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

C20H31N3O5 (393.2263596)


   

2-methoxy-N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

2-methoxy-N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

C20H31N3O5 (393.2263596)


   

2-methoxy-N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

2-methoxy-N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

C20H31N3O5 (393.2263596)


   

2-[(2R,5S,6R)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide

2-[(2R,5S,6R)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide

C20H31N3O5 (393.2263596)


   

2-[(2R,5R,6S)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide

2-[(2R,5R,6S)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide

C20H31N3O5 (393.2263596)


   

2-[(2R,5R,6R)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide

2-[(2R,5R,6R)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide

C20H31N3O5 (393.2263596)


   

2-[(2S,5R,6R)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide

2-[(2S,5R,6R)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide

C20H31N3O5 (393.2263596)


   

N-ethyl-N-[[(2S,3R,4R)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1-(pyridin-3-ylmethyl)azetidin-2-yl]methyl]acetamide

N-ethyl-N-[[(2S,3R,4R)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1-(pyridin-3-ylmethyl)azetidin-2-yl]methyl]acetamide

C24H31N3O2 (393.2416146)


   

N-[[(2S,3R,4S)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-N-(2-methylpropyl)pyridine-2-carboxamide

N-[[(2S,3R,4S)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-N-(2-methylpropyl)pyridine-2-carboxamide

C24H31N3O2 (393.2416146)


   

(2S,3S,4R)-2-cyano-3-[2-(1-cyclohexenyl)phenyl]-N-cyclohexyl-4-(hydroxymethyl)-1-azetidinecarboxamide

(2S,3S,4R)-2-cyano-3-[2-(1-cyclohexenyl)phenyl]-N-cyclohexyl-4-(hydroxymethyl)-1-azetidinecarboxamide

C24H31N3O2 (393.2416146)


   

2-methoxy-N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

2-methoxy-N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

C20H31N3O5 (393.2263596)


   

2-methoxy-N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

2-methoxy-N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

C20H31N3O5 (393.2263596)


   

2-methoxy-N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

2-methoxy-N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

C20H31N3O5 (393.2263596)


   

2-methoxy-N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

2-methoxy-N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

C20H31N3O5 (393.2263596)


   

2-methoxy-N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

2-methoxy-N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

C20H31N3O5 (393.2263596)


   

2-methoxy-N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

2-methoxy-N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

C20H31N3O5 (393.2263596)


   

2-methoxy-N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

2-methoxy-N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

C20H31N3O5 (393.2263596)


   

2-methoxy-N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

2-methoxy-N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

C20H31N3O5 (393.2263596)


   

2-methoxy-N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

2-methoxy-N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide

C20H31N3O5 (393.2263596)


   

2-[(2S,5R,6S)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide

2-[(2S,5R,6S)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide

C20H31N3O5 (393.2263596)


   

2-[(2S,5S,6R)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide

2-[(2S,5S,6R)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide

C20H31N3O5 (393.2263596)


   

2-[(2S,5S,6S)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide

2-[(2S,5S,6S)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide

C20H31N3O5 (393.2263596)


   

2-[(2R,5S,6S)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide

2-[(2R,5S,6S)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide

C20H31N3O5 (393.2263596)


   

(2R,3S,4R)-2-cyano-3-[4-(1-cyclohexenyl)phenyl]-N-cyclohexyl-4-(hydroxymethyl)-1-azetidinecarboxamide

(2R,3S,4R)-2-cyano-3-[4-(1-cyclohexenyl)phenyl]-N-cyclohexyl-4-(hydroxymethyl)-1-azetidinecarboxamide

C24H31N3O2 (393.2416146)


   

(2S,3R,4R)-2-cyano-3-[4-(1-cyclohexenyl)phenyl]-N-cyclohexyl-4-(hydroxymethyl)-1-azetidinecarboxamide

(2S,3R,4R)-2-cyano-3-[4-(1-cyclohexenyl)phenyl]-N-cyclohexyl-4-(hydroxymethyl)-1-azetidinecarboxamide

C24H31N3O2 (393.2416146)


   

N-[[(2S,3S,4S)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-N-(2-methylpropyl)pyridine-2-carboxamide

N-[[(2S,3S,4S)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-N-(2-methylpropyl)pyridine-2-carboxamide

C24H31N3O2 (393.2416146)


   
   
   
   
   
   
   

N-[(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-icosatetraenoyl]glycine

N-[(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-icosatetraenoyl]glycine

C22H35NO5 (393.25151000000005)


An N-acylglycine resulting from the formal condensation of the amino group of glycine with the carboxy group of (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-icosatetraenoic acid.

   

N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]glycine

N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]glycine

C22H35NO5 (393.25151000000005)


An N-acylglycine resulting from the formal condensation of the amino group of glycine with the carboxy group of (12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoic acid.

   
   

(8E,10Z,13Z,15E,19Z)-7,17-bis(hydroperoxy)docosa-8,10,13,15,19-pentaenoate

(8E,10Z,13Z,15E,19Z)-7,17-bis(hydroperoxy)docosa-8,10,13,15,19-pentaenoate

C22H33O6- (393.22770180000003)


   

HexCer 9:0;2O/3:0

HexCer 9:0;2O/3:0

C18H35NO8 (393.236255)


   

HexCer 8:0;2O/4:0

HexCer 8:0;2O/4:0

C18H35NO8 (393.236255)


   

HexCer 10:0;2O/2:0

HexCer 10:0;2O/2:0

C18H35NO8 (393.236255)


   
   

1-(3-{6-(1H-indol-3-yl)-3-[(2S)-2-methylbutanamido]pyrazin-2-yl}propyl)guanidine

1-(3-{6-(1H-indol-3-yl)-3-[(2S)-2-methylbutanamido]pyrazin-2-yl}propyl)guanidine

C21H27N7O (393.2276972)


   

PD 128042

2,2-Dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide

C23H39NO4 (393.28789340000003)


D004791 - Enzyme Inhibitors PD 128042 (CI 976) is a potent, orally active, and selective inhibitor of ACAT (acyl coenzyme A:cholesterol acyltransferase) with an IC50s of 73 nM. PD 128042 is also a potent LPAT (lysophospholipid acyltransferase) inhibitor. PD 128042 inhibits Golgi-associated LPAT activity (IC50=15 μM). PD 128042 inhibits multiple membrane trafficking steps, including ones found in the endocytic and secretory pathway[1][2][3].

   

N-hexadecanoyl-histidine

N-hexadecanoyl-histidine

C22H39N3O3 (393.2991264)


   

Nonadecaphing-4-enine-1-phosphate

Nonadecaphing-4-enine-1-phosphate

C19H40NO5P (393.2643960000001)


   

(8E,10Z,13Z,15E,19Z)-7,17-bis(hydroperoxy)docosapentaenoate

(8E,10Z,13Z,15E,19Z)-7,17-bis(hydroperoxy)docosapentaenoate

C22H33O6 (393.22770180000003)


A hydroperoxydocosapentaenoate that is the conjugate base of (8E,10Z,13Z,15E,19Z)-7,17-bis(hydroperoxy)docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,11Z,13Z,15E,17S)-10,17-bis(hydroperoxy)docosapentaenoate

(4Z,7Z,11Z,13Z,15E,17S)-10,17-bis(hydroperoxy)docosapentaenoate

C22H33O6 (393.22770180000003)


A hydroperoxydocosapentaenoate that is the conjugate base of (4Z,7Z,11Z,13Z,15E,17S)-10,17-bis(hydroperoxy)docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   
   
   
   
   
   
   
   
   
   

(1s,2r,3r,4r,5s,6r,8s,9r,10s,13s,14s,16r,17s)-11-ethyl-6,16-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,14-triol

(1s,2r,3r,4r,5s,6r,8s,9r,10s,13s,14s,16r,17s)-11-ethyl-6,16-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,14-triol

C22H35NO5 (393.25151000000005)


   

(1r,3s,5s,7s,10r,11s,12r,13s,15s)-7-ethyl-3,11,12-trihydroxy-12-(hydroxymethyl)-5-methyl-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecan-7-ium-7-olate

(1r,3s,5s,7s,10r,11s,12r,13s,15s)-7-ethyl-3,11,12-trihydroxy-12-(hydroxymethyl)-5-methyl-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecan-7-ium-7-olate

C22H35NO5 (393.25151000000005)


   

n-(2-{4-[(3-hydroxy-3,7-dimethylocta-4,6-dien-1-yl)oxy]phenyl}ethyl)benzenecarboximidic acid

n-(2-{4-[(3-hydroxy-3,7-dimethylocta-4,6-dien-1-yl)oxy]phenyl}ethyl)benzenecarboximidic acid

C25H31NO3 (393.2303816)


   

2-[(1r,2e,4ar,4br,7s,8ar,10s,10as)-7,10-dihydroxy-1,4b,8,8-tetramethyl-decahydro-1h-phenanthren-2-ylidene]-n-(2-hydroxyethyl)-n-methylacetamide

2-[(1r,2e,4ar,4br,7s,8ar,10s,10as)-7,10-dihydroxy-1,4b,8,8-tetramethyl-decahydro-1h-phenanthren-2-ylidene]-n-(2-hydroxyethyl)-n-methylacetamide

C23H39NO4 (393.28789340000003)


   

11-ethyl-13-(hydroxymethyl)-6-methoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16-triol

11-ethyl-13-(hydroxymethyl)-6-methoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16-triol

C22H35NO5 (393.25151000000005)


   

n-{4-[(4s)-5-methyl-2-oxo-4-phenyl-1,5-diazocan-1-yl]butyl}benzenecarboximidic acid

n-{4-[(4s)-5-methyl-2-oxo-4-phenyl-1,5-diazocan-1-yl]butyl}benzenecarboximidic acid

C24H31N3O2 (393.2416146)


   

(1s,2r,3r,4s,5s,6s,8r,9r,10r,13r,16s,17r,18s)-11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16,18-tetrol

(1s,2r,3r,4s,5s,6s,8r,9r,10r,13r,16s,17r,18s)-11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16,18-tetrol

C22H35NO5 (393.25151000000005)


   

11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16,18-tetrol

11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16,18-tetrol

C22H35NO5 (393.25151000000005)


   

5-[(1r,15s,17s,18s)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraen-6-yl]-4,5-dihydro-3h-pyrrol-2-ol

5-[(1r,15s,17s,18s)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraen-6-yl]-4,5-dihydro-3h-pyrrol-2-ol

C24H31N3O2 (393.2416146)


   

(3s,6s)-3-methyl-6-{[5-(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-3,6-dihydropyrazine-2,5-diol

(3s,6s)-3-methyl-6-{[5-(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-3,6-dihydropyrazine-2,5-diol

C24H31N3O2 (393.2416146)


   

n-[2-(4-{[(3s,4e)-3-hydroxy-3,7-dimethylocta-4,6-dien-1-yl]oxy}phenyl)ethyl]benzenecarboximidic acid

n-[2-(4-{[(3s,4e)-3-hydroxy-3,7-dimethylocta-4,6-dien-1-yl]oxy}phenyl)ethyl]benzenecarboximidic acid

C25H31NO3 (393.2303816)


   

(1r,4r,5r,6s,8s,9s,13r,16s)-11-ethyl-6,16-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,5,8-triol

(1r,4r,5r,6s,8s,9s,13r,16s)-11-ethyl-6,16-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,5,8-triol

C22H35NO5 (393.25151000000005)


   

(1r,2s,5r,9r,10r,11s,12r,13s,15r,16r)-7-ethyl-2,11,12-trihydroxy-12-(hydroxymethyl)-5-methyl-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecan-7-ium-7-olate

(1r,2s,5r,9r,10r,11s,12r,13s,15r,16r)-7-ethyl-2,11,12-trihydroxy-12-(hydroxymethyl)-5-methyl-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecan-7-ium-7-olate

C22H35NO5 (393.25151000000005)


   

(1s,2r,3r,4r,5s,6r,8r,9r,10s,13r,16s,17r)-11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol

(1s,2r,3r,4r,5s,6r,8r,9r,10s,13r,16s,17r)-11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol

C22H35NO5 (393.25151000000005)


   

4-methoxy-5-{[(2e)-5-undecylpyrrol-2-ylidene]methyl}-1h,1'h-2,2'-bipyrrole

4-methoxy-5-{[(2e)-5-undecylpyrrol-2-ylidene]methyl}-1h,1'h-2,2'-bipyrrole

C25H35N3O (393.277998)


   

11-ethyl-4,6-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,13,16-triol

11-ethyl-4,6-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,13,16-triol

C22H35NO5 (393.25151000000005)


   

3-methyl-6-{[7-(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-3,6-dihydropyrazine-2,5-diol

3-methyl-6-{[7-(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-3,6-dihydropyrazine-2,5-diol

C24H31N3O2 (393.2416146)


   

(e,5e)-4-methoxy-5-[(5-undecyl-1h-pyrrol-2-yl)methylidene]-1h-2,2'-bipyrrolylidene

(e,5e)-4-methoxy-5-[(5-undecyl-1h-pyrrol-2-yl)methylidene]-1h-2,2'-bipyrrolylidene

C25H35N3O (393.277998)


   

(3s,6s)-3-methyl-6-{[7-(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-3,6-dihydropyrazine-2,5-diol

(3s,6s)-3-methyl-6-{[7-(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-3,6-dihydropyrazine-2,5-diol

C24H31N3O2 (393.2416146)


   

2-[(3e,5e)-2-hydroxy-6,10-dimethylundeca-3,5,9-trien-2-yl]-4-methyl-2h,3h-furo[3,2-c]quinolin-5-ium-5-olate

2-[(3e,5e)-2-hydroxy-6,10-dimethylundeca-3,5,9-trien-2-yl]-4-methyl-2h,3h-furo[3,2-c]quinolin-5-ium-5-olate

C25H31NO3 (393.2303816)


   

11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol

11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol

C22H35NO5 (393.25151000000005)


   

11-ethyl-6,16-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,14-triol

11-ethyl-6,16-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,14-triol

C22H35NO5 (393.25151000000005)


   

7-ethyl-12-(hydroxymethyl)-5-methyl-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-3,4,11,12-tetrol

7-ethyl-12-(hydroxymethyl)-5-methyl-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-3,4,11,12-tetrol

C22H35NO5 (393.25151000000005)


   

(1s,2r,3r,4s,5s,6r,8r,9r,10s,13r,16s,17r)-11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol

(1s,2r,3r,4s,5s,6r,8r,9r,10s,13r,16s,17r)-11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol

C22H35NO5 (393.25151000000005)


   

(5z)-4-methoxy-5-[(5-undecyl-1h-pyrrol-2-yl)methylidene]-1'h-2,2'-bipyrrole

(5z)-4-methoxy-5-[(5-undecyl-1h-pyrrol-2-yl)methylidene]-1'h-2,2'-bipyrrole

C25H35N3O (393.277998)


   

(1s,2s,3s,4r,5r,6r,8r,9r,10s,13s,14s,16r,17s)-11-ethyl-6,16-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,14-triol

(1s,2s,3s,4r,5r,6r,8r,9r,10s,13s,14s,16r,17s)-11-ethyl-6,16-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,14-triol

C22H35NO5 (393.25151000000005)


   

4-methoxy-5-[(5-undecyl-1h-pyrrol-2-yl)methylidene]-1'h-2,2'-bipyrrole

4-methoxy-5-[(5-undecyl-1h-pyrrol-2-yl)methylidene]-1'h-2,2'-bipyrrole

C25H35N3O (393.277998)


   

(2s)-2-[(2r,3e,5e)-2-hydroxy-6,10-dimethylundeca-3,5,9-trien-2-yl]-4-methyl-2h,3h-furo[3,2-c]quinolin-5-ium-5-olate

(2s)-2-[(2r,3e,5e)-2-hydroxy-6,10-dimethylundeca-3,5,9-trien-2-yl]-4-methyl-2h,3h-furo[3,2-c]quinolin-5-ium-5-olate

C25H31NO3 (393.2303816)


   

2-(2-hydroxy-6,10-dimethylundeca-3,5,9-trien-2-yl)-4-methyl-2h,3h-furo[3,2-c]quinolin-5-ium-5-olate

2-(2-hydroxy-6,10-dimethylundeca-3,5,9-trien-2-yl)-4-methyl-2h,3h-furo[3,2-c]quinolin-5-ium-5-olate

C25H31NO3 (393.2303816)


   

(1s,2r,3r,4s,5s,6s,8r,9r,10s,13r,16s,17r)-11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol

(1s,2r,3r,4s,5s,6s,8r,9r,10s,13r,16s,17r)-11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol

C22H35NO5 (393.25151000000005)


   

2-(7,10-dihydroxy-1,4b,8,8-tetramethyl-decahydro-1h-phenanthren-2-ylidene)-n-(2-hydroxyethyl)-n-methylacetamide

2-(7,10-dihydroxy-1,4b,8,8-tetramethyl-decahydro-1h-phenanthren-2-ylidene)-n-(2-hydroxyethyl)-n-methylacetamide

C23H39NO4 (393.28789340000003)


   

(1s,2r,3r,4s,5s,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-13-(hydroxymethyl)-6-methoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16-triol

(1s,2r,3r,4s,5s,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-13-(hydroxymethyl)-6-methoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16-triol

C22H35NO5 (393.25151000000005)


   

(1r,2r,3r,4s,5r,6r,8s,9s,10r,13r,16s,17r)-11-ethyl-6,16-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,5,8-triol

(1r,2r,3r,4s,5r,6r,8s,9s,10r,13r,16s,17r)-11-ethyl-6,16-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,5,8-triol

C22H35NO5 (393.25151000000005)


   

3-methyl-6-{[5-(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-3,6-dihydropyrazine-2,5-diol

3-methyl-6-{[5-(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-3,6-dihydropyrazine-2,5-diol

C24H31N3O2 (393.2416146)


   

(1r,3s,5s,8r,9r,10r,11s,12r,13s,15s,16r)-7-ethyl-3,11,12-trihydroxy-12-(hydroxymethyl)-5-methyl-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecan-7-ium-7-olate

(1r,3s,5s,8r,9r,10r,11s,12r,13s,15s,16r)-7-ethyl-3,11,12-trihydroxy-12-(hydroxymethyl)-5-methyl-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecan-7-ium-7-olate

C22H35NO5 (393.25151000000005)


   

n-[2-(4-{[(2e)-4-hydroxy-3,7-dimethylocta-2,6-dien-1-yl]oxy}phenyl)ethyl]benzenecarboximidic acid

n-[2-(4-{[(2e)-4-hydroxy-3,7-dimethylocta-2,6-dien-1-yl]oxy}phenyl)ethyl]benzenecarboximidic acid

C25H31NO3 (393.2303816)


   

(1s,2r,3r,4r,5s,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-13-(hydroxymethyl)-6-methoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16-triol

(1s,2r,3r,4r,5s,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-13-(hydroxymethyl)-6-methoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,16-triol

C22H35NO5 (393.25151000000005)


   

(1r,2r,3r,4s,5s,6s,8s,9s,10r,13r,14r,16s,17r)-11-ethyl-6,16-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,14-triol

(1r,2r,3r,4s,5s,6s,8s,9s,10r,13r,14r,16s,17r)-11-ethyl-6,16-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,14-triol

C22H35NO5 (393.25151000000005)


   

5-[(4-heptyl-5-methyl-3-propyl-1h-pyrrol-2-yl)methylidene]-4-methoxy-1'h-2,2'-bipyrrole

5-[(4-heptyl-5-methyl-3-propyl-1h-pyrrol-2-yl)methylidene]-4-methoxy-1'h-2,2'-bipyrrole

C25H35N3O (393.277998)


   

(1r,2s,3s,4s,5s,6r,8r,9r,10s,13r,16r,17r)-11-ethyl-4,6-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,13,16-triol

(1r,2s,3s,4s,5s,6r,8r,9r,10s,13r,16r,17r)-11-ethyl-4,6-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,13,16-triol

C22H35NO5 (393.25151000000005)


   

n-[4-(5-methyl-2-oxo-4-phenyl-1,5-diazocan-1-yl)butyl]benzenecarboximidic acid

n-[4-(5-methyl-2-oxo-4-phenyl-1,5-diazocan-1-yl)butyl]benzenecarboximidic acid

C24H31N3O2 (393.2416146)


   

(5e)-5-[(4-heptyl-5-methyl-3-propyl-1h-pyrrol-2-yl)methylidene]-4-methoxy-1'h-2,2'-bipyrrole

(5e)-5-[(4-heptyl-5-methyl-3-propyl-1h-pyrrol-2-yl)methylidene]-4-methoxy-1'h-2,2'-bipyrrole

C25H35N3O (393.277998)


   

2-({2-[(3-amino-1,2-dihydroxy-4-phenylbutylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-3-methylbutanoic acid

2-({2-[(3-amino-1,2-dihydroxy-4-phenylbutylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-3-methylbutanoic acid

C20H31N3O5 (393.2263596)


   

undecylprodigiosin red pigment

undecylprodigiosin red pigment

C25H35N3O (393.277998)